AP2184A - Benzimidazolone compounds having 5-HT4 receptor agonistic activity. - Google Patents

Benzimidazolone compounds having 5-HT4 receptor agonistic activity.

Info

Publication number
AP2184A
AP2184A AP2006003536A AP2006003536A AP2184A AP 2184 A AP2184 A AP 2184A AP 2006003536 A AP2006003536 A AP 2006003536A AP 2006003536 A AP2006003536 A AP 2006003536A AP 2184 A AP2184 A AP 2184A
Authority
AP
ARIPO
Prior art keywords
agonistic activity
receptor agonistic
benzimidazolone compounds
benzimidazolone
compounds
Prior art date
Application number
AP2006003536A
Other languages
English (en)
Other versions
AP2006003536A0 (en
Inventor
Satoru Iguchi
Yasuhiro Katsu
Takashi Kojima
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003536A0 publication Critical patent/AP2006003536A0/xx
Application granted granted Critical
Publication of AP2184A publication Critical patent/AP2184A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2006003536A 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-HT4 receptor agonistic activity. AP2184A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50014403P 2003-09-03 2003-09-03
PCT/IB2004/002741 WO2005021539A1 (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-ht4 receptor agonistic activity

Publications (2)

Publication Number Publication Date
AP2006003536A0 AP2006003536A0 (en) 2006-04-30
AP2184A true AP2184A (en) 2010-12-02

Family

ID=34272920

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003536A AP2184A (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-HT4 receptor agonistic activity.

Country Status (39)

Country Link
US (2) US7776885B2 (de)
EP (1) EP1664036B1 (de)
JP (1) JP3983269B1 (de)
KR (1) KR100738784B1 (de)
CN (1) CN100482659C (de)
AP (1) AP2184A (de)
AR (1) AR045552A1 (de)
AT (1) ATE539077T1 (de)
AU (1) AU2004268840B9 (de)
BR (1) BRPI0414105B8 (de)
CA (1) CA2537127C (de)
CR (1) CR8267A (de)
CY (1) CY1112321T1 (de)
DK (1) DK1664036T3 (de)
EA (1) EA009457B1 (de)
EC (1) ECSP066407A (de)
ES (1) ES2377484T3 (de)
GE (1) GEP20084527B (de)
GT (1) GT200400174A (de)
HR (1) HRP20120077T1 (de)
IL (3) IL173705A (de)
IS (1) IS8289A (de)
MA (1) MA28021A1 (de)
MX (1) MXPA06002550A (de)
NL (1) NL1026959C2 (de)
NO (1) NO20061519L (de)
OA (1) OA13248A (de)
PA (1) PA8610601A1 (de)
PE (1) PE20050874A1 (de)
PL (1) PL1664036T3 (de)
PT (1) PT1664036E (de)
RS (1) RS20060145A (de)
SI (1) SI1664036T1 (de)
TN (1) TNSN06073A1 (de)
TW (1) TW200510332A (de)
UA (1) UA86204C2 (de)
UY (1) UY28496A1 (de)
WO (1) WO2005021539A1 (de)
ZA (1) ZA200601324B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
ES2332808T3 (es) 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
MX2007007818A (es) 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
AP2007004067A0 (en) * 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
EA013567B1 (ru) 2005-03-02 2010-06-30 Тереванс, Инк. Хинолиноновые соединения в качестве агонистов рецептора 5-ht
WO2006097808A1 (en) * 2005-03-15 2006-09-21 Pfizer Japan Inc. Benzimidazolone derivatives as cb2 receptor ligands
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
WO2006133104A2 (en) * 2005-06-07 2006-12-14 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
JP5209480B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
EP1937670A1 (de) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolone mit aktivität am m1-rezeptor
ES2391107T3 (es) 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
TW200736227A (en) * 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007086541A2 (en) * 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20080318964A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched eszopiclone
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
JP6023926B2 (ja) * 2010-02-12 2016-11-09 株式会社ＡｓｋＡｔ 認知症治療のための５−ｈｔ４受容体アゴニスト
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US20120143119A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of Serotonin Receptor Antagonists By Microinjection Systems
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
WO2017093890A1 (en) * 2015-11-30 2017-06-08 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
KR102748218B1 (ko) * 2020-10-23 2024-12-31 에이치케이이노엔 주식회사 벤즈이미다졸 유도체 화합물을 포함하는 구강붕해정 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522914A1 (de) * 1991-06-27 1993-01-13 Synthelabo 2-Piperidinylpyrimidin-4-Carboxamidderivate, deren Herstellung und deren Verwendung als Heilmittel
WO2000037461A1 (en) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
WO2002053568A1 (en) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63716A (en) * 1867-04-09 Improved cheery stoner
CH566987A5 (de) * 1972-04-21 1975-09-30 Ciba Geigy Ag
US3945953A (en) * 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
CA2148700A1 (en) 1992-11-05 1994-05-11 Laramie Mary Gaster Piperidine derivatives as 5-ht4 receptor antagonists
TW252206B (de) * 1993-09-01 1995-07-21 Philips Electronics Nv
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU9309898A (en) 1997-09-09 1999-03-29 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522914A1 (de) * 1991-06-27 1993-01-13 Synthelabo 2-Piperidinylpyrimidin-4-Carboxamidderivate, deren Herstellung und deren Verwendung als Heilmittel
WO2000037461A1 (en) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
WO2002053568A1 (en) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds

Also Published As

Publication number Publication date
CA2537127C (en) 2011-04-05
SI1664036T1 (sl) 2012-03-30
JP2007533613A (ja) 2007-11-22
HK1093338A1 (zh) 2007-03-02
ECSP066407A (es) 2006-09-18
ATE539077T1 (de) 2012-01-15
ES2377484T3 (es) 2012-03-28
BRPI0414105B1 (pt) 2018-08-14
MXPA06002550A (es) 2006-06-20
EA009457B1 (ru) 2007-12-28
CN1845922A (zh) 2006-10-11
IL205600A0 (en) 2010-11-30
AU2004268840B9 (en) 2011-02-03
NL1026959A1 (nl) 2005-03-07
IS8289A (is) 2006-02-09
PA8610601A1 (es) 2005-03-28
AU2004268840B2 (en) 2010-09-23
HRP20120077T1 (hr) 2012-02-29
RS20060145A (sr) 2008-06-05
GT200400174A (es) 2005-05-02
AU2004268840A1 (en) 2005-03-10
AP2006003536A0 (en) 2006-04-30
UA86204C2 (uk) 2009-04-10
JP3983269B1 (ja) 2007-09-26
IL173705A (en) 2013-04-30
IL173705A0 (en) 2006-07-05
AR045552A1 (es) 2005-11-02
WO2005021539A1 (en) 2005-03-10
MA28021A1 (fr) 2006-07-03
EP1664036A1 (de) 2006-06-07
NL1026959C2 (nl) 2006-01-23
CN100482659C (zh) 2009-04-29
TNSN06073A1 (en) 2007-10-03
KR20060087540A (ko) 2006-08-02
PT1664036E (pt) 2012-02-16
US20050148573A1 (en) 2005-07-07
BRPI0414105B8 (pt) 2021-05-25
PE20050874A1 (es) 2005-10-26
UY28496A1 (es) 2005-04-29
GEP20084527B (en) 2008-11-10
DK1664036T3 (da) 2012-02-13
CY1112321T1 (el) 2015-12-09
ZA200601324B (en) 2007-05-30
EA200600327A1 (ru) 2006-08-25
BRPI0414105A (pt) 2006-11-21
PL1664036T3 (pl) 2012-04-30
TW200510332A (en) 2005-03-16
KR100738784B1 (ko) 2007-07-12
IL205599A0 (en) 2010-11-30
US7776885B2 (en) 2010-08-17
NO20061519L (no) 2006-06-01
CA2537127A1 (en) 2005-03-10
EP1664036B1 (de) 2011-12-28
OA13248A (en) 2007-01-31
US20100273794A1 (en) 2010-10-28
CR8267A (es) 2006-11-21

Similar Documents

Publication Publication Date Title
AP2184A (en) Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
IL160945A0 (en) Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
AU2002353403A8 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
IL174990A0 (en) Compounds having crth2 antagonist activity
IL178086A0 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
PL1687390T3 (pl) Zgazowanie katalityczne
IL173079A0 (en) Ppar active compounds
GB0325093D0 (en) Fiberglass nonwoven catalyst
MA27306A1 (fr) Ligands des recepteurs de la melanocortine.
EP1631559A4 (de) Il-8-rezeptorantagonisten
GB0203412D0 (en) 5-HT 2B receptor antagonists
IS2897B (is) Efnasambönd sem hamla gegn virkni kalkviðtaka
EP1616880A4 (de) Ligand mit agonistischer aktivität gegen einen mutierten rezeptor
SI1558259T1 (sl) Sečninski derivati kot IL-8 receptorski antagonisti
SG131946A1 (en) Ccr3 receptor antagonists
IL173337A0 (en) Receptor
ZA200804010B (en) Carbamate compounds as 5-HT4 receptor agonists
GB0215389D0 (en) Receptor
SI1648867T1 (sl) Ppar aktivne spojine
GB0321998D0 (en) Receptor
GB0329104D0 (en) Receptor
TJ403B (en) Dibaferrol, having antimicrobe activity.
ES1052119Y (es) Maquina reactivadora de cortes de calzado.
AU149317S (en) Sanitary ware for pets
GB0204278D0 (en) Animal activity unit